Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Revelation Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
REVB
Nasdaq
8731
https://www.revbiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Revelation Biosciences Inc
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
- May 10th, 2024 8:52 pm
REVB Begins Trials with Good Cash on Hand
- Mar 25th, 2024 11:06 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
- Mar 22nd, 2024 8:15 pm
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
- Mar 13th, 2024 1:00 pm
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
- Mar 12th, 2024 1:00 pm
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
- Mar 4th, 2024 2:00 pm
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
- Feb 13th, 2024 2:00 pm
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
- Feb 5th, 2024 9:41 pm
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
- Feb 1st, 2024 11:00 am
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
- Jan 30th, 2024 2:00 pm
REVB Continues March to Trials
- Jan 26th, 2024 11:18 am
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
- Jan 23rd, 2024 2:00 pm
REVB Releases Earnings and Prepares for Trials
- Nov 14th, 2023 11:41 am
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
- Nov 13th, 2023 9:05 pm
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
- Oct 12th, 2023 1:00 pm
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
- Oct 4th, 2023 1:00 pm
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
- Oct 2nd, 2023 1:00 pm
REVB Reports Solid Balance Sheet and Remains on Track
- Aug 14th, 2023 11:36 am
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
- Aug 11th, 2023 8:10 pm
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
- Jun 29th, 2023 1:00 pm
Scroll